BACKGROUND:NeuroThera Effectiveness and Safety Trials (NEST) 1 and 2 have demonstrated safety of transcranial laser therapy (TLT) for human treatment in acute ischemic stroke. NEST 1 study suggested efficacy of TLT but the following NEST 2, despite strong signals, missed reaching significance on its primary efficacy endpoint. In order to assess efficacy in a larger cohort, a pooled analysis was therefore performed. METHODS: The two studies were first compared for heterogeneity, and then a pooled analysis was performed to assess overall safety and efficacy, and examined particular subgroups. The primary endpoint for the pooled analysis was dichotomized modified Rankin scale (mRS) 0-2 at 90 days. RESULTS: Efficacy analysis for the intention-to-treat population was based on a total of 778 patients. Baseline characteristics and prognostic factors were balanced between the two groups. The TLT group (n = 410) success rate measured by the dichotomized 90-day mRS was significantly higher compared with the sham group (n = 368) (P = 0·003, OR: 1·67, 95% CI: 1·19-2·35). The distribution of scores on the 90-day mRS was significantly different in TLT compared with sham (P = 0·0005 Cochran-Mantel-Haenszel). Subgroup analysis identified moderate strokes as a predictor of better treatment response. CONCLUSIONS: This pooled analysis support the likelihood that transcranial laser therapy is effective for the treatment of acute ischemic stroke when initiated within 24 h of stroke onset. If ultimately confirmed, transcranial laser therapy will change management and improve outcomes of far more patients with acute ischemic stroke.
RCT Entities:
BACKGROUND: NeuroThera Effectiveness and Safety Trials (NEST) 1 and 2 have demonstrated safety of transcranial laser therapy (TLT) for human treatment in acute ischemic stroke. NEST 1 study suggested efficacy of TLT but the following NEST 2, despite strong signals, missed reaching significance on its primary efficacy endpoint. In order to assess efficacy in a larger cohort, a pooled analysis was therefore performed. METHODS: The two studies were first compared for heterogeneity, and then a pooled analysis was performed to assess overall safety and efficacy, and examined particular subgroups. The primary endpoint for the pooled analysis was dichotomized modified Rankin scale (mRS) 0-2 at 90 days. RESULTS: Efficacy analysis for the intention-to-treat population was based on a total of 778 patients. Baseline characteristics and prognostic factors were balanced between the two groups. The TLT group (n = 410) success rate measured by the dichotomized 90-day mRS was significantly higher compared with the sham group (n = 368) (P = 0·003, OR: 1·67, 95% CI: 1·19-2·35). The distribution of scores on the 90-day mRS was significantly different in TLT compared with sham (P = 0·0005 Cochran-Mantel-Haenszel). Subgroup analysis identified moderate strokes as a predictor of better treatment response. CONCLUSIONS: This pooled analysis support the likelihood that transcranial laser therapy is effective for the treatment of acute ischemic stroke when initiated within 24 h of stroke onset. If ultimately confirmed, transcranial laser therapy will change management and improve outcomes of far more patients with acute ischemic stroke.
Authors: Amir Oron; Uri Oron; Jieli Chen; Anda Eilam; Chunling Zhang; Menachem Sadeh; Yair Lampl; Jackson Streeter; Luis DeTaboada; Michael Chopp Journal: Stroke Date: 2006-08-31 Impact factor: 7.914
Authors: Luis Detaboada; Sanja Ilic; Sandra Leichliter-Martha; Uri Oron; Amir Oron; Jackson Streeter Journal: Lasers Surg Med Date: 2006-01 Impact factor: 4.025
Authors: Justin A Zivin; Gregory W Albers; Natan Bornstein; Thomas Chippendale; Bjorn Dahlof; Thomas Devlin; Marc Fisher; Werner Hacke; William Holt; Sanja Ilic; Scott Kasner; Robert Lew; Marshall Nash; Julio Perez; Marilyn Rymer; Peter Schellinger; Dietmar Schneider; Stefan Schwab; Roland Veltkamp; Michael Walker; Jackson Streeter Journal: Stroke Date: 2009-02-20 Impact factor: 7.914
Authors: Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni Journal: N Engl J Med Date: 2008-09-25 Impact factor: 91.245
Authors: Yair Lampl; Justin A Zivin; Marc Fisher; Robert Lew; Lennart Welin; Bjorn Dahlof; Peter Borenstein; Bjorn Andersson; Julio Perez; Cesar Caparo; Sanja Ilic; Uri Oron Journal: Stroke Date: 2007-04-26 Impact factor: 7.914
Authors: Paolo Cassano; Cristina Cusin; David Mischoulon; Michael R Hamblin; Luis De Taboada; Angela Pisoni; Trina Chang; Albert Yeung; Dawn F Ionescu; Samuel R Petrie; Andrew A Nierenberg; Maurizio Fava; Dan V Iosifescu Journal: Psychiatry J Date: 2015-08-19
Authors: James Giordano; Marom Bikson; Emily S Kappenman; Vincent P Clark; H Branch Coslett; Michael R Hamblin; Roy Hamilton; Ryan Jankord; Walter J Kozumbo; R Andrew McKinley; Michael A Nitsche; J Patrick Reilly; Jessica Richardson; Rachel Wurzman; Edward Calabrese Journal: Dose Response Date: 2017-02-09 Impact factor: 2.658